Corvus Pharmaceuticals, Inc. Earnings Per Share (Basic)
Corvus Pharmaceuticals, Inc. (CRVS) reported Earnings Per Share (Basic) of -$0.19 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-06
- Corvus Pharmaceuticals, Inc. earnings per share, basic for the quarter ending 2026-06-30 was -$0.19.
- Corvus Pharmaceuticals, Inc. earnings per share, basic for the quarter ending 2026-03-31 was -$0.15, a 171.43% decline year-over-year.
- Corvus Pharmaceuticals, Inc. earnings per share, basic for the quarter ending 2025-12-31 was -$0.15.
- Corvus Pharmaceuticals, Inc. earnings per share, basic for the quarter ending 2025-09-30 was -$0.12.
- Corvus Pharmaceuticals, Inc. earnings per share, basic for fiscal 2025 was -$0.19.
- Corvus Pharmaceuticals, Inc. earnings per share, basic for fiscal 2024 was -$1.02.
- Corvus Pharmaceuticals, Inc. earnings per share, basic for fiscal 2023 was -$0.56.
- Corvus Pharmaceuticals, Inc. earnings per share, basic for fiscal 2022 was -$0.89.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$0.19 10-Q · filed 2026-08-06 | -$0.35 10-Q · filed 2026-08-06 | -$0.50 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$0.62 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2026-03-31 | -$0.15 10-Q · filed 2026-05-07 | -$0.30 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$0.42 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$0.53 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2025-12-31 | -$0.15 derived: net income ÷ weighted average shares · filed 2026-03-12 | -$0.27 derived: net income ÷ weighted average shares · filed 2026-03-12 | -$0.38 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$0.19 10-K · filed 2026-03-12 |
| 2025-09-30 | -$0.12 10-Q · filed 2025-11-04 | -$0.23 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$0.04 10-Q · filed 2025-11-04 | -$0.20 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2025-06-30 | -$0.10 10-Q · filed 2026-08-06 | $0.10 10-Q · filed 2026-08-06 | -$0.07 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$0.63 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2025-03-31 | $0.21 10-Q · filed 2026-05-07 | $0.04 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$0.54 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$0.62 derived: net income ÷ weighted average shares · filed 2026-05-07 |
| 2024-12-31 | -$0.18 derived: net income ÷ weighted average shares · filed 2026-03-12 | -$0.77 derived: net income ÷ weighted average shares · filed 2026-03-12 | -$0.87 derived: net income ÷ weighted average shares · filed 2026-03-12 | -$1.02 10-K · filed 2026-03-12 |
| 2024-09-30 | -$0.60 10-Q · filed 2025-11-04 | -$0.70 derived: net income ÷ weighted average shares · filed 2025-11-04 | -$0.86 10-Q · filed 2025-11-04 | |
| 2024-06-30 | -$0.07 10-Q · filed 2025-08-07 | -$0.18 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | -$0.12 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | -$0.56 10-K · filed 2026-03-12 | |||
| 2023-09-30 | -$0.12 10-Q · filed 2024-11-12 | -$0.43 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | -$0.14 10-Q · filed 2024-08-06 | -$0.31 10-Q · filed 2024-08-06 | ||
| 2023-03-31 | -$0.17 10-Q · filed 2024-05-07 | |||
| 2022-12-31 | -$0.89 10-K · filed 2025-03-25 | |||
| 2022-09-30 | -$0.32 10-Q · filed 2023-11-07 | -$0.68 10-Q · filed 2023-11-07 | ||
| 2022-06-30 | -$0.18 10-Q · filed 2023-08-08 | -$0.36 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | -$0.18 10-Q · filed 2023-05-08 | |||
| 2021-12-31 | -$0.20 10-K · filed 2022-03-10 | -$1.03 10-K · filed 2024-03-19 | ||
| 2021-09-30 | -$0.24 10-Q · filed 2022-11-03 | -$0.84 10-Q · filed 2022-11-03 | ||
| 2021-06-30 | -$0.28 10-Q · filed 2022-08-08 | -$0.61 10-Q · filed 2022-08-08 | ||
| 2021-03-31 | -$0.34 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | $0.92 10-K · filed 2022-03-10 | -$0.20 10-K · filed 2023-03-28 | ||
| 2020-09-30 | -$0.33 10-K · filed 2022-03-10 | |||
| 2020-06-30 | -$0.36 10-K · filed 2022-03-10 | |||
| 2020-03-31 | -$0.44 10-K · filed 2022-03-10 | |||
| 2019-12-31 | -$1.59 10-K · filed 2022-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Apnimed, Inc. (APMD) | United States | $0.899B |